Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2025-08-25 Governance Information
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
董事会议事规则
Governance Information Classification · 100% confidence The document is titled "广东永顺生物制药股份有限公司董事会议事规则" which translates to "Rules of Procedure for the Board of Directors of Guangdong Yongshun Biopharmaceutical Co., Ltd." It details the internal governance rules, procedures for board meetings, voting, powers of the board, and related corporate governance matters. It references relevant laws and regulations and outlines the structure and responsibilities of the board. There is no financial data, no audit information, no earnings or capital updates, no voting results, no legal proceedings, and no mention of report publication or announcements. The content is focused on governance practices and internal rules of the board. Therefore, the document fits the category of Governance Information (CGR). The document length is sufficient and it is not a mere announcement or certification, so it is not RPA or RNS. Confidence is high due to the clear and detailed governance content.
2025-08-25 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the period January 1, 2025 to June 30, 2025. It contains detailed financial data including income, profit, assets, liabilities, and operational details. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It includes sections such as accounting data, business overview, financial analysis, and risk disclosures. The presence of comprehensive financial statements and management discussion confirms it is a substantive interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese
关于召开2025年第一次临时股东会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2025 first extraordinary general meeting (临时股东会) of Guangdong Yongshun Biopharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), agenda items for shareholder approval, registration details, and proxy authorization forms. The content focuses on the announcement and procedural details of the shareholder meeting rather than the results or minutes of the meeting. It is not a report of voting results, nor a management or financial report. The document is a formal meeting notice and invitation to shareholders to participate and vote on various corporate governance and management proposals. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2025-08-25 Chinese
第五届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and the voting results on several proposals, including the cancellation of the Supervisory Board and amendments to the company bylaws, as well as the approval of the 2025 semi-annual report and the reappointment of the audit firm. The document does not contain the actual semi-annual report or financial statements but references where those reports can be found. It is a formal announcement of meeting resolutions rather than a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure.
2025-08-25 Chinese
重大信息内部报告制度
Governance Information Classification · 95% confidence The document is titled '重大信息内部报告制度' which translates to 'Major Information Internal Reporting System'. It is a detailed internal policy document outlining the procedures, responsibilities, and scope of reporting major information within the company. It includes sections on the definition of major information, reporting obligations, procedures, management, and responsibilities. The document is not a financial report, earnings release, or announcement of voting results. It is not a regulatory filing or a report publication announcement since it is a substantive internal governance document. It fits best under Governance Information (CGR) as it details the company's internal rules and governance practices related to information disclosure and reporting.
2025-08-25 Chinese
独立董事提名人声明与承诺
Board/Management Information Classification · 95% confidence The document is a formal announcement from Guangdong Yongshun Biopharmaceutical Co., Ltd. nominating a candidate for the position of independent director on the company's board. It includes detailed statements and commitments regarding the nominee's qualifications, independence, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management changes, specifically the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or certification, so it is not RPA or RNS.
2025-08-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.